Research Analysts Set Expectations for Actinium Pharmaceuticals, Inc.’s FY2026 Earnings (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Actinium Pharmaceuticals in a research report issued on Monday, April 29th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of $4.10 for the year, up from their prior estimate of $3.86. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2027 earnings at $7.94 EPS and FY2028 earnings at $10.75 EPS.

Other analysts have also recently issued reports about the stock. Maxim Group raised their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th. StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.72.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM opened at $7.43 on Tuesday. Actinium Pharmaceuticals has a 12-month low of $4.00 and a 12-month high of $9.86. The company has a market capitalization of $218.44 million, a PE ratio of -4.06 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.21. The firm had revenue of $0.08 million for the quarter.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ATNM. Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals in the 1st quarter valued at approximately $78,000. Creative Financial Designs Inc. ADV boosted its holdings in Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Finally, Brandywine Global Investment Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the 3rd quarter valued at about $1,033,000. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.